A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
News|Articles|September 11, 2026
5 Years of Lung Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
Author(s)Quincy Attobrah
Fact checked by: CURE staff
Lung cancer treatment has changed rapidly since 2021, with new targeted drugs, immunotherapy and treatments designed to overcome resistance.
Advertisement
Advertisement
Lung cancer treatment has changed a lot in five years. If you or someone you love has lung cancer, it helps to know not just that things have improved, but how — because the pattern behind these changes is the best clue we have for what's coming next. Here's the story, year by year, told partly through doctors and patients CURE has interviewed along the way.
Related to this article
A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between caution, optimism and daily life.
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
Advertisement
Advertisement